SEAVI Advent Private Equity announces that it has fully exited its holdings in Xuan Wu Cloud Technology Holding

SEAVI Advent Private Equity today announced that it has fully exited its holdings in Xuan Wu Cloud Technology Holding (Stock Code: 02392.HK), a leading intelligent Customer Relationship Management SaaS company focused on serving mid and large-cap enterprise customers in the People’s Republic of China.

SEAVI Advent’s investment in Xuan Wu during the Covid-19 period supported the company’s capital markets strategy and helped in its international expansion into Southeast Asia, Latin America, Middle East and other regions. Since its IPO, Xuan Wu has successfully increased the number of clients serviced from 2640 in FY2021 to over 3000 clients in FY2025. SEAVI Advent was also instrumental in guiding the company’s directors and senior management in their new role as executives of a listed company.

Moving forward, the company under their new majority owners is poised to enter the next stage of growth, with a focus on the use of AI and Cloud Communication in its proprietary cPaaS platform.

Kevin CHAN, Managing Partner of SEAVI Advent, said: “We are pleased to have worked with the management team of Xuan Wu and helped reach numerous milestones together such as the company’s listing on the Mainboard of the Hong Kong Stock Exchange. Even though we are divesting from the company, we believe the company is now positioned to move to even greater heights and further excel in its business.”

About SEAVI Advent Private Equity

SEAVI Advent Private Equity, is one of the first private equity and venture capital firms to operate in the Asia Pacific region. Since 1984, the firm has invested over US$600 million into more than 120 Asian companies, from growth to late stage, as well as buyout and control transactions.

With a proven track record that includes ranking fourth on Preqin’s Top 10 performance funds for its 2003/04 vintage, SEAVI Advent has been instrumental in delivering value to many of its portfolio companies while developing an extensive record of successful investments, which include Universal Health International Group (2211.HK), Hainan Shuangcheng Pharmaceutical Co. Ltd (002693.SZ), and Clarity Medical Group (1406.HK) in the healthcare sector; Weimob Inc. (2013.HK), Huitongda Network (9878.HK), and Sinofriends in the TMT sector; and Tsaker New Energy (1986.HK), and Pengyao Group (300664.SZ) in the new energy & advanced manufacturing sector.